Today, mental health assessments rely solely on patients reporting their symptoms which are by nature, subjective. Such subjectivity often impacts symptom reporting and therefore incorrect diagnosis and treatment.
Medibio’s technology will aid clinicians in the early detection of mental health conditions and empower individuals to screen and better understand their mental health.
Medibio’s technology focuses on screening for depressive symptoms – known as a depressive burden.
Data obtained from electroencephalographic (EEG) and electrocardiogram (ECG) recordings are processed through our proprietary algorithms in; sleep, nocturnal heart rate, and heart rate variability (HRV). The structural components of Medibio’s algorithms are developed based on Artificial Intelligence (AI). The algorithm development, build, and testing are supported by clinical pre-validation trials. These trials are followed by validation-to-commercialization trials performed with the highest FDA standards and according to the Agency regulations. Each clinical step of our validation process is consulted and presented to the FDA regulatory body for final approval.
Autonomic activity is the link between the brain and the heart. The autonomic nervous system (ANS) plays an important role in physiological situations and various pathological settings.
The determination of depressive burden is achieved by combining objective biomarkers of sleep macro and microstructures to heart rate and heart rate variability, to map autonomic modulation throughout sleep staging. The autonomic modulation is one of Medibio’s proprietary and novel technological features.
MEBsleep is a software-only medical device that analyses Electroencephalogram (EEG) and Electrocardiogram (ECG) data collected during polysomnography to verify sleep stages and heart rate variability (HRV) in patients suffering from primary or secondary sleep disturbances. MEBsleep uses artificial intelligence, machine learning and deep learning methods of algorithm development to analyse large amounts of raw data, including autonomic nervous system modulation throughout sleep stages, to highlight key information to assist the physician in understanding the patient’s condition.
Currently, the gold standard for identifying sleep stages in a sleep laboratory setting is a 60 to 90-minute visual assessment conducted by sleep technicians. MEBsleep performs the same assessment in 60 to 90 seconds, thereby providing improved efficacy for overall patient evaluation by sleep medicine technicians, under the supervision of a physician.